Literature DB >> 16934497

Recruitment and activation of naive T cells in the islets by lymphotoxin beta receptor-dependent tertiary lymphoid structure.

Youjin Lee1, Robert K Chin, Peter Christiansen, Yonglian Sun, Alexei V Tumanov, Jing Wang, Alexander V Chervonsky, Yang-Xin Fu.   

Abstract

The development of spontaneous insulin-dependent diabetes mellitus is preceded by the organization of tertiary lymphoid organ (TLO) in situ, but its role in the development of tissue destruction and the cytokines that control such structures have not been fully defined. We have now observed that TNF superfamily 14 (TNFSF14) is upregulated in aged nonobese diabetic (NOD) pancreas with the appearance of TLO. Blockade of TNFSF14 signaling caused a substantial reduction in the expression of lymphotoxin beta receptor (LTbetaR)-controlled migration factors within the islets and disrupts organization of tertiary structures, leading to prevention of diabetes. Consistently, enhancing LTbetaR signaling by transgenic expression of TNFSF14 in the islets of NOD mice rapidly promoted de novo formation of local TLO, resulting in diabetes, even in the absence of draining lymph nodes (LN). Thus, the TNFSF14-LTbetaR pathway appears to be critical in the development and maintenance of TLO for the onset of diabetes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16934497     DOI: 10.1016/j.immuni.2006.06.016

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  68 in total

1.  New immune therapy targets tumor-associated environment: from bone marrow to tumor site.

Authors:  Yang-Xin Fu
Journal:  Cell Mol Immunol       Date:  2011-12-12       Impact factor: 11.530

Review 2.  New insights into the development of lymphoid tissues.

Authors:  Serge A van de Pavert; Reina E Mebius
Journal:  Nat Rev Immunol       Date:  2010-08-13       Impact factor: 53.106

3.  Role of lymphotoxin and homeostatic chemokines in the development and function of local lymphoid tissues in the respiratory tract.

Authors:  Javier Rangel-Moreno; Damian Carragher; Troy D Randall
Journal:  Inmunologia       Date:  2007

Review 4.  Costimulatory and coinhibitory receptors in anti-tumor immunity.

Authors:  Gregory Driessens; Justin Kline; Thomas F Gajewski
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

Review 5.  Immunoregulation by tumor necrosis factor superfamily member LIGHT.

Authors:  Yugang Wang; Mingzhao Zhu; Mendy Miller; Yang-Xin Fu
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

Review 6.  Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy.

Authors:  Haidong Tang; Mingzhao Zhu; Jian Qiao; Yang-Xin Fu
Journal:  Cell Mol Immunol       Date:  2017-04-17       Impact factor: 11.530

7.  Heterogeneous fibroblasts underlie age-dependent tertiary lymphoid tissues in the kidney.

Authors:  Yuki Sato; Akiko Mii; Yoko Hamazaki; Harumi Fujita; Hirosuke Nakata; Kyoko Masuda; Shingo Nishiyama; Shinsuke Shibuya; Hironori Haga; Osamu Ogawa; Akira Shimizu; Shuh Narumiya; Tsuneyasu Kaisho; Makoto Arita; Masashi Yanagisawa; Masayuki Miyasaka; Kumar Sharma; Nagahiro Minato; Hiroshi Kawamoto; Motoko Yanagita
Journal:  JCI Insight       Date:  2016-07-21

Review 8.  The central role of antigen presentation in islets of Langerhans in autoimmune diabetes.

Authors:  Boris Calderon; Javier A Carrero; Emil R Unanue
Journal:  Curr Opin Immunol       Date:  2013-11-16       Impact factor: 7.486

9.  Prevention of diabetes by FTY720-mediated stabilization of peri-islet tertiary lymphoid organs.

Authors:  Cristina Penaranda; Qizhi Tang; Nancy H Ruddle; Jeffrey A Bluestone
Journal:  Diabetes       Date:  2010-03-18       Impact factor: 9.461

10.  Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis.

Authors:  Jean-Pierre Vartanian; Michel Henry; Agnès Marchio; Rodolphe Suspène; Marie-Ming Aynaud; Denise Guétard; Minerva Cervantes-Gonzalez; Carlo Battiston; Vincenzo Mazzaferro; Pascal Pineau; Anne Dejean; Simon Wain-Hobson
Journal:  PLoS Pathog       Date:  2010-05-27       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.